Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Merck
Express Scripts
Mallinckrodt
Dow

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ZOLOFT

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Zoloft

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000440 Sertraline and Naltrexone for Alcohol Dependence Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 1969-12-31 This study is a double-blind, placebo-controlled outpatient trial to improve, through the addition of sertraline (Zoloft), the abstinence and relapse rates in alcohol- dependent individuals currently taking naltrexone (Revia).
NCT00000446 Drug Treatment for Alcoholics With Post-Traumatic Stress Disorder Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 1969-12-31 This study will investigate the use of sertraline (Zoloft) to decrease alcohol consumption and crime-related post-traumatic stress disorder in those individuals with both disorders. This will be a 12-week, placebo-controlled, double-blind outpatient trial. All subjects will receive cognitive behavioral therapy in addition to a placebo or sertraline. Comprehensive evaluation will be done at study entry; treatment termination; and 6, 9, and 12 months after study entry.
NCT00000451 Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline) Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 2003-01-01 This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in Alaska natives with alcohol dependence. The study will also examine whether a combination of naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used alone. Alaska Native individuals will be recruited into a 16 week outpatient study.
NCT00000451 Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline) Completed Yale University Phase 2 2003-01-01 This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in Alaska natives with alcohol dependence. The study will also examine whether a combination of naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used alone. Alaska Native individuals will be recruited into a 16 week outpatient study.
NCT00000458 Sertraline and Cognitive Therapy in Depressed Alcoholics Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 1969-12-31 This study will assess whether individuals treated with sertraline (Zoloft) and cognitive behavior therapy will experience improvement with their depression and consume less alcohol than individuals treated with a placebo and cognitive behavior therapy. This is a 12-week, random assignment, placebo-controlled, double-blind study with followup assessments 1 and 3 months after treatment.
NCT00001483 Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression Completed National Institute of Mental Health (NIMH) Phase 2 1995-06-01 This study will compare the effectiveness of relatively new antidepressants which have different mechanisms of action. Buproprion (Wellbutrin) works on dopamine and the dopaminergic pathway. Sertraline (Zoloft) works as a selective serotonin reuptake inhibitor (SSRI). Venlafaxine (Effexor) works as a mixed serotonin, norepinephrine, and dopamine reuptake inhibitor. Subjects enrolled in this study will be patients diagnosed with a bipolar disorder who are presently taking medication to prevent the symptoms of the disease (prophylactic treatment), but have had breakthrough episodes of depression despite taking their medication. Patients will receive any one of the three antidepressant medications as noted above plus a placebo inactive sugar pill, in order to mask which antidepressant is being prescribed) in addition to their regular medication for bipolar disorder. All of the doses will be calculated as effective for the treatment of a unipolar major depressive disorder. The patient will continue receiving the medication for ten weeks. The effectiveness of the drug treatment will be measured by using three different scales; 1. Inventory for Depressive Symptoms - Clinicians form (IDS-C) 2. Clinical Global Impression scale(CGI-BP) 3. Life Charting Methodology (LCM) Patients who do not respond to their medication within ten weeks from the beginning of the study will be considered as non-responders and be offered the opportunity to start the study again, taking one of the two remaining medications. For example, if a patient was assigned to take Wellbutrin but it was ineffective, he/she could re-enter the study and be given either Zoloft or Effexor. Patients that do respond in the first ten weeks of the study will be eligible to continue taking the medication for one year to assess the long term effectiveness of the drug on preventing episodes of depression and to assess for any possible differential induction of mania.
NCT00004554 Sertraline for Alcohol Dependence and Depression Completed University of Pennsylvania Phase 4 2000-01-01 This study will examine depressed alcoholic outpatients to assess whether combining naltrexone (Revia) and sertraline (Zoloft) will result in greater reductions in both drinking and depression over either medication alone or placebo. A secondary aim is to determine whether certain patient features will predict response to sertraline, naltrexone or the combination of the two drugs. Subjects will be randomized into treatment groups for 14 weeks. The followup phase includes two visits at 6 and 9 months after treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zoloft

Condition Name

Condition Name for Zoloft
Intervention Trials
Depression 32
Healthy 15
Major Depressive Disorder 15
Alcoholism 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Zoloft
Intervention Trials
Depression 57
Depressive Disorder 51
Disease 29
Depressive Disorder, Major 25
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Zoloft

Trials by Country

Trials by Country for Zoloft
Location Trials
United States 191
Canada 12
Australia 7
Spain 4
India 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Zoloft
Location Trials
New York 20
California 19
Pennsylvania 15
North Carolina 11
Texas 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Zoloft

Clinical Trial Phase

Clinical Trial Phase for Zoloft
Clinical Trial Phase Trials
Phase 4 47
Phase 3 14
Phase 2/Phase 3 5
[disabled in preview] 45
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Zoloft
Clinical Trial Phase Trials
Completed 85
Recruiting 15
Terminated 9
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Zoloft

Sponsor Name

Sponsor Name for Zoloft
Sponsor Trials
National Institute of Mental Health (NIMH) 27
Pfizer 13
National Institute on Alcohol Abuse and Alcoholism (NIAAA) 6
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Zoloft
Sponsor Trials
Other 118
NIH 46
Industry 39
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Express Scripts
Johnson and Johnson
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.